Foundayo Medicare BALANCE Model: $50/Month Starting July 1, 2026
What is publicly known (as of May 2026)
- Price tier:$50/month out-of-pocket for eligible Medicare Part D enrollees, per Eli Lilly's announced terms.
- Effective date: July 1, 2026.
- Eligibility: Medicare Part D enrollees, subject to plan-level formulary inclusion. Full eligibility verification mechanics are still being published.
- No CVD requirement:Unlike Wegovy's ASCVD-only Medicare path (post 2024 cardiovascular indication expansion), the Foundayo BALANCE Model does not appear to require a non-weight-loss diagnosis.
- Cash-pay floor: LillyDirect at $149/month for the 0.8 mg lowest dose remains available to Medicare beneficiaries before, during, and after the BALANCE Model launch - it is a direct-to-consumer program, not copay-assistance, so federal anti-kickback rules do not block it.
What is still emerging
1. Which Part D plans have added Foundayo at the BALANCE Model tier. Part D plans run formulary updates on quarterly review cycles, and Foundayo only received FDA approval on April 1, 2026 - too recent for the Q2 2026 cycle in many cases. Expect broader formulary inclusion through Q3 2026. Check your specific plan's member portal or call Member Services to confirm Foundayo coverage status.
2. The exact CMS or PBM mechanism.The announcement uses the "BALANCE Model" phrasing; the underlying CMS or PBM program structure is still being detailed publicly. The most likely mechanisms are either (a) a direct manufacturer subsidy bringing patient out-of-pocket to $50 regardless of how the plan classifies Foundayo, or (b) negotiated formulary placement with major Part D plan sponsors.
3. Interaction with the Medicare Modernization Act.Section 1860D-2(e)(2)(A) excludes “drugs when used for anorexia, weight loss, or weight gain” from Part D. Lilly has structured Foundayo terms to include Medicare-eligible patients at the $50 tier despite that exclusion. This is one of the first negotiated workarounds for a weight-loss-only-indicated GLP-1 on Medicare. The legal architecture here will be relevant for future GLP-1 launches if it holds.
What to do before July 1, 2026
- Get a prescription now. Foundayo has been FDA-approved and available via LillyDirect, retail (CVS, Walgreens), and Ro since April 2026. The prescription is the same whether you intend to pay via Medicare or via cash.
- Pay cash via LillyDirect for the May-June bridge. $149/month for the lowest dose at lilly.com/lillydirect/medicines/foundayo. Stay within the 45-day refill window to keep that tier.
- After July 1, check your Part D plan's formulary.Look for "Foundayo" or "orforglipron" on the preferred drug list. If listed, your plan should honor the $50/month BALANCE Model pricing for eligible enrollees.
- If your plan has not added Foundayo, file a formulary exception. Your prescriber submits documentation; the plan has 72 hours for a standard decision, 24 hours for expedited.
- Keep LillyDirect on speed-dial as backup. Even after July 1, if your specific plan has not added Foundayo at the BALANCE Model tier, LillyDirect cash-pay at $149/month may still beat your plan's copay. Run the math both ways.
Frequently asked questions
What is the Medicare BALANCE Model for Foundayo?
The Medicare BALANCE Model is the shorthand for Eli Lilly's announced Medicare Part D pricing tier for Foundayo (orforglipron), starting July 1, 2026. Under the announced terms, eligible Medicare Part D enrollees pay as low as $50/month for Foundayo. This is unusual for a weight-loss GLP-1 because the Medicare Modernization Act of 2003 statutorily excludes drugs prescribed solely for weight loss from Part D coverage, and Foundayo is FDA-approved for chronic weight management - so the $50/month tier represents a structured workaround for Medicare beneficiaries who otherwise could not access Part D-covered weight-loss GLP-1s without documented cardiovascular disease.
When does the BALANCE Model take effect?
July 1, 2026, per Eli Lilly's announced launch terms. Before that date, Medicare beneficiaries access Foundayo by paying cash through LillyDirect at $149/month for the lowest dose, with higher doses up to $299/month within the 45-day refill window. After July 1, eligible Part D enrollees can pay $50/month - if their specific Part D plan has added Foundayo to its formulary at the BALANCE Model tier.
Who is eligible for the $50/month BALANCE Model price?
Per Eli Lilly's announced terms, eligible Medicare Part D enrollees. Full eligibility verification details are still being published as the launch date approaches. Confirm with your specific Part D plan administrator after July 1, 2026. Medicare Advantage plans handle GLP-1s plan-by-plan; coverage varies. Medicaid coverage is determined state-by-state and is not the same program as the BALANCE Model.
How does this differ from Wegovy Medicare coverage?
Wegovy gained limited Medicare Part D coverage in March 2024 after the FDA expanded its label to include cardiovascular risk reduction in ASCVD patients (based on the SELECT trial). To get Wegovy covered by Medicare, you need documented atherosclerotic cardiovascular disease on your chart - prior MI, prior stroke, prior peripheral artery disease, or prior coronary/peripheral revascularization. Without ASCVD, Medicare denies Wegovy. The Foundayo BALANCE Model does not appear to require a non-weight-loss indication. This makes Foundayo the more accessible Medicare GLP-1 path for the much larger population of beneficiaries who have obesity but do not yet have qualifying cardiovascular disease.
Is my Part D plan required to offer Foundayo at $50/month?
Part D plans administer their own formularies and decide whether to add Foundayo at the BALANCE Model tier. Plans typically run formulary updates on quarterly review cycles, and Foundayo only received FDA approval on April 1, 2026 - too recent for the Q2 2026 formulary cycle in many cases. Expect broader Part D formulary inclusion through Q3 2026. If your specific plan has not added Foundayo by July 1, you can file a formulary exception request through your plan, or use LillyDirect cash-pay as a backup.
What if my Part D plan does not add Foundayo at the BALANCE Model tier?
Two paths. (1) File a Part D formulary exception request through your plan - your prescriber submits documentation citing Foundayo's unique status as the only daily oral GLP-1 with no food or water restrictions. Decisions are typically 7-14 days for standard, 24 hours for expedited. (2) Use LillyDirect cash-pay at $149/month for the lowest dose. Medicare status does NOT exclude you from LillyDirect - it is a direct-to-consumer cash-pay program, not a copay-assistance program, so the federal anti-kickback statute that bars Medicare patients from manufacturer savings cards does not apply.
Does the BALANCE Model price work for Medicare Advantage too?
Medicare Advantage plans are required to cover at least everything traditional Medicare + Part D covers, but they administer their own formularies and prior-auth requirements. Some MA plans (especially those that consider obesity care a quality measure) may add Foundayo at the BALANCE Model tier faster than traditional Part D plans. Check your specific Medicare Advantage plan's formulary on its member portal after July 1, 2026.
Is the BALANCE Model the same as a manufacturer savings card?
No. Manufacturer savings cards (like the Foundayo Savings Card for commercial insurance, or the Wegovy / Zepbound Savings Cards) are blocked by federal anti-kickback statute for patients with any government insurance - Medicare, Medicaid, Tricare, VA. The BALANCE Model appears to be a separate program structured to be compatible with Medicare beneficiary status (most likely via direct manufacturer pricing or negotiated Part D placement, rather than a copay-assistance mechanism). It is Foundayo-specific; there is no Wegovy BALANCE Model or Zepbound BALANCE Model in 2026.
How does Foundayo Medicare pricing compare to Wegovy and Zepbound?
Foundayo BALANCE Model (announced): $50/month for eligible Part D enrollees starting July 1, 2026, no cardiovascular disease requirement. Wegovy Medicare: covered only for ASCVD patients per the 2024 FDA label expansion, typical Part D copay $30-$100/month. Zepbound Medicare: not currently covered for any indication - same statutory exclusion that previously blocked all weight-loss GLP-1s. If Foundayo BALANCE Model executes as announced, it is the most accessible Medicare GLP-1 path in 2026 for beneficiaries who have obesity but no qualifying cardiovascular disease.
What if I have Medicare + Extra Help (Low-Income Subsidy)?
Extra Help / LIS typically reduces Part D copays to $0-$11/month for covered drugs in 2026. If your Part D plan covers Foundayo at the BALANCE Model tier and you qualify for full LIS, your out-of-pocket could be below the $50/month announced floor. LIS does not help if Foundayo is not yet on your plan's formulary - in that case the underlying coverage gap matters more than the subsidy.
Related guides
Track Foundayo (orforglipron) pricing and availability
Eli Lilly's daily oral pill Foundayo (orforglipron) was FDA-approved April 1, 2026 and starts at $149/mo via LillyDirect. We'll email you when pricing tiers change, insurance coverage expands, or new head-to-head data lands vs. Wegovy and Zepbound.